despit current trough valuat maintain hold believ
issu pharmedium busi impend layoff memphi facil
 suspended/cancel licens facil provid overhang
overshadow slight tailwind gener price stabil rel stabil
brand drug price result adjust ep ebitda estim toward
lower end guidanc
stabil gener deflat tailwind distributor
proprietari work gener price trend note link management commentari
around stabl competit environ suggest sell-sid gener deflat
larg stabil back histor norm coupl continu product
ration among gener manufactur suggest first time
last year gener price trend modest tailwind
distributor group
in-lin brand drug price start larg remov risk guidanc cut
announc jan brand drug price increas come in-lin
distributor expect mid-single-digit think risk potenti revenu
earn guidanc cut investor concern dec larg gone point
said regulatori risk particularli surround physician reimburs medicar
part-b remain concern especi regulatori reform end caus shift
patient volum physician offic commun set institution
impend layoff memphi facil continu state licensur issu lower
confid pharmedium abil contribut meaning ebitda
last week news surround impend layoff pharmedium memphi
facil coupl fact state licens suspensions/cancel
pharmedium facil resolv date see pg detail
believ timelin return busi previou level oper
profit take longer anticip give us lower confid abil
pharmedium busi provid meaning ebitda contribut
adjust estim lower end guidanc rang result lower
recent convers w/ management suggest lower end guidanc rang
includ assumpt pharmedium memphi facil remain close
remaind fiscal year seem increasingli like given impend layoff
lack fda inspect resourc w/ government shutdown said unsur
level productivity/product ramp assum guidanc
pharmedium facil adjust ep ebitda
estim toward lower end guidanc rang
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
maintain hold believ issu
pharmedium busi impend layoff memphi
facil suspended/cancel licens facil
provid overhang overshadow slight tailwind
gener price stabil rel stabil
brand drug price
 magnitud number brand drug price increas
 updat pharmedium memphi facil remedi effort
 sell-sid gener deflat continu stabil move
brand inflat remain mid-single-digit
 abc specialti distribut busi along mwi
segment busi help off-set nt
 capit deploy primarili focus capital-expenditure
strateg buyback provid sharehold
 sell-sid gener deflat moder expect
abl continu leverag wbad yield improv
gener margin profit dollar
 brand inflat begin increas high-singl digit
number brand drug increas normal
 pharmedium issu resolv sooner anticip
allow busi contribut margin
five-year multipl pt
doubl digit
 brand inflat continu moder low-singl
digit manufactur choos increas price
annual less
 pharmedium facil closur extend and/or order
dont return pre-closur level facil re-open
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
jefferi state board pharmaci
pleas see import disclosur inform page report
